Curis Lifesciences IPO

Incorporated in 2010, Curis Lifesciences Limited is a pharmaceutical company engaged in the development, manufacturing, and distribution of a wide range of pharmaceutical products. The company operates both globally and domestically on a loan licence or contract manufacturing basis, along with its own brand marketing. It caters to over 100 corporate clients and serves two international clients in Yemen and Kenya. Its product portfolio includes tablets, capsules, oral liquids, external preparations, and sterile ophthalmic ointments, manufactured at its advanced Sanand, Gujarat facility.

Curis Lifesciences Limited IPO Overview

Curis Lifesciences Limited IPO is a book-built issue valued at ₹27.52 crore, comprising an entirely fresh issue of 0.22 crore equity shares. The IPO will open for subscription on 7 November 2025 and close on 11 November 2025. The basis of allotment is expected to be finalised on 12 November 2025, while the company’s shares are proposed to be listed on the NSE SME platform with a tentative listing date of 14 November 2025.

The price band for the issue has been set between ₹120 and ₹128 per share, and the lot size is 1,000 shares. The minimum investment required for retail investors is ₹2,56,000 (based on the upper price band), while High Net-worth Individuals (HNIs) can apply for a minimum of three lots (3,000 shares), amounting to ₹3,84,000.

Finaax Capital Advisors Private Limited is the Book Running Lead Manager of the issue, and MUFG Intime India Private Limited serves as the Registrar. The Market Maker for the Curis Lifesciences IPO is RS Wealth Management Private Limited.

Curis Lifesciences Limited IPO Details

Particulars	Details
IPO Date	7 November 2025 to 11 November 2025
Listing Date	14 November 2025
Face Value	₹10 per share
Issue Price Band	₹120 to ₹128 per share
Lot Size	1,000 Shares
Total Issue Size	21,50,000 shares (aggregating up to ₹27.52 Crore)
Fresh Issue	21,50,000 shares (aggregating up to ₹27.52 Crore)
Offer for Sale	NA
Issue Type	Book-building IPO
Listing At	NSE SME
Share Holding Pre Issue	59,34,434 shares (≈92.68%)
Share Holding Post Issue	80,84,434 shares (≈68.03%)
Market Maker Portion	1,08,000 shares

Curis Lifesciences Limited IPO Reservation

Investor Category	Shares Offered
Market Maker	1,08,000 (≈5.02%)
QIB	10,18,000 (≈47.35%)
NII (HNI)	3,08,000 (≈14.33%)
Retail	7,16,000 (≈33.30%)
Total Shares Offered	21,50,000 (100%)

Curis Lifesciences Limited IPO Lot Size

Application	Lots	Shares	Amount
Retail (Min)	2	2,000	₹2,56,000
Retail (Max)	2	2,000	₹2,56,000
S-HNI (Min)	3	3,000	₹3,84,000
S-HNI (Max)	7	7,000	₹8,96,000

Curis Lifesciences Limited IPO Promoter Holding

Shareholding Status	Percentage
Pre-Issue	92.68%
Post-Issue	68.03%

Curis Lifesciences Limited IPO Valuation Overview

KPI	Value
Earnings Per Share (EPS)	₹10.29
Price/Earnings (P/E)	~12.44×
Return on Net Worth (RoNW)	37.62%
Net Asset Value (NAV)	₹27.34 per share
Return on Equity (ROE)	55.25%
Return on Capital Employed (ROCE)	27.83%
EBITDA Margin	19.41%
PAT Margin	12.43%
Debt to Equity Ratio	0.96

Objectives of the Proceeds

• Capital expenditure towards up-gradation of manufacturing facilities: ₹2.44 Cr

• Capital expenditure towards construction of storage facility: ₹3.62 Cr

• Pre-payment/repayment of outstanding secured loans: ₹1.86 Cr

• Product registrations in other countries: ₹2.69 Cr

• Funding working capital requirements: ₹11.25 Cr

•  General corporate purposes: amount unspecified

Key Financials (in ₹ crore)

Particulars	31 Jul 2025	31 Mar 2025	31 Mar 2024	31 Mar 2023
Assets	56.29	42.53	33.88	29.75
Total Income	19.51	49.65	35.87	36.42
Profit After Tax (PAT)	2.87	6.11	4.87	1.88
Reserves and Surplus	13.16	10.29	5.37	0.51
Total Borrowings	15.32	15.62	17.09	16.19